Cargando…

Exploring the potential of combining IL-2-activated NK cells with an anti-PDL1 monoclonal antibody to target multiple myeloma-associated macrophages

Multiple myeloma (MM) is an incurable disease, characterized by malignant plasma cells in the bone marrow. MM growth is largely dependent on the tumor microenvironment (TME), consisting of complex cellular networks that shape a tumor-permissive environment. Within the TME, tumor-associated cells (TA...

Descripción completa

Detalles Bibliográficos
Autores principales: Ehlers, Femke A. I., Mahaweni, Niken M., van de Waterweg Berends, Annet, Saya, Thara, Bos, Gerard M. J., Wieten, Lotte
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10198883/
https://www.ncbi.nlm.nih.gov/pubmed/36656341
http://dx.doi.org/10.1007/s00262-022-03365-4
_version_ 1785044822600450048
author Ehlers, Femke A. I.
Mahaweni, Niken M.
van de Waterweg Berends, Annet
Saya, Thara
Bos, Gerard M. J.
Wieten, Lotte
author_facet Ehlers, Femke A. I.
Mahaweni, Niken M.
van de Waterweg Berends, Annet
Saya, Thara
Bos, Gerard M. J.
Wieten, Lotte
author_sort Ehlers, Femke A. I.
collection PubMed
description Multiple myeloma (MM) is an incurable disease, characterized by malignant plasma cells in the bone marrow. MM growth is largely dependent on the tumor microenvironment (TME), consisting of complex cellular networks that shape a tumor-permissive environment. Within the TME, tumor-associated cells (TAC) comprise heterogeneous cell populations that collectively support immunosuppression. Reshaping the TME toward an immunostimulatory environment may enhance effectiveness of immunotherapies. Here, we investigated interactions between donor-derived natural killer (NK) cells and TAC, like tumor-associated macrophages (TAM) and M1 macrophages, and assessed whether anti-tumor effector functions of NK cells could be enhanced by an ADCC-triggering antibody targeting macrophages. Monocytes were polarized in vitro toward either M1 or TAM before co-culture with high-dose IL-2-activated NK cells. NK cell responses were assessed by measuring degranulation (CD107a) and IFN-γ production. We found that NK cells degranulated and produced IFN-γ upon interaction with both macrophage types. NK cell responses against PD-L1(+) M1 macrophages could be further enhanced by Avelumab, an anti-PD-L1- and ADCC-inducing antibody. Additionally, NK cell responses were influenced by HLA class I, shown by stronger degranulation in NK cell subsets for which the corresponding HLA ligand was absent on the macrophage target cells (KIR-ligand mismatch) compared to degranulation in the presence of the HLA ligand (KIR-ligand match). Our results suggest that NK cells could, next to killing tumor cells, get activated upon interaction with TAC, like M1 macrophages and TAMs, and that NK cells combined with PD-L1 blocking antibodies with ADCC potential could, through IFN-γ secretion, promote a more immune-favorable TME. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s00262-022-03365-4.
format Online
Article
Text
id pubmed-10198883
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Springer Berlin Heidelberg
record_format MEDLINE/PubMed
spelling pubmed-101988832023-05-21 Exploring the potential of combining IL-2-activated NK cells with an anti-PDL1 monoclonal antibody to target multiple myeloma-associated macrophages Ehlers, Femke A. I. Mahaweni, Niken M. van de Waterweg Berends, Annet Saya, Thara Bos, Gerard M. J. Wieten, Lotte Cancer Immunol Immunother Original Article Multiple myeloma (MM) is an incurable disease, characterized by malignant plasma cells in the bone marrow. MM growth is largely dependent on the tumor microenvironment (TME), consisting of complex cellular networks that shape a tumor-permissive environment. Within the TME, tumor-associated cells (TAC) comprise heterogeneous cell populations that collectively support immunosuppression. Reshaping the TME toward an immunostimulatory environment may enhance effectiveness of immunotherapies. Here, we investigated interactions between donor-derived natural killer (NK) cells and TAC, like tumor-associated macrophages (TAM) and M1 macrophages, and assessed whether anti-tumor effector functions of NK cells could be enhanced by an ADCC-triggering antibody targeting macrophages. Monocytes were polarized in vitro toward either M1 or TAM before co-culture with high-dose IL-2-activated NK cells. NK cell responses were assessed by measuring degranulation (CD107a) and IFN-γ production. We found that NK cells degranulated and produced IFN-γ upon interaction with both macrophage types. NK cell responses against PD-L1(+) M1 macrophages could be further enhanced by Avelumab, an anti-PD-L1- and ADCC-inducing antibody. Additionally, NK cell responses were influenced by HLA class I, shown by stronger degranulation in NK cell subsets for which the corresponding HLA ligand was absent on the macrophage target cells (KIR-ligand mismatch) compared to degranulation in the presence of the HLA ligand (KIR-ligand match). Our results suggest that NK cells could, next to killing tumor cells, get activated upon interaction with TAC, like M1 macrophages and TAMs, and that NK cells combined with PD-L1 blocking antibodies with ADCC potential could, through IFN-γ secretion, promote a more immune-favorable TME. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s00262-022-03365-4. Springer Berlin Heidelberg 2023-01-19 2023 /pmc/articles/PMC10198883/ /pubmed/36656341 http://dx.doi.org/10.1007/s00262-022-03365-4 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Original Article
Ehlers, Femke A. I.
Mahaweni, Niken M.
van de Waterweg Berends, Annet
Saya, Thara
Bos, Gerard M. J.
Wieten, Lotte
Exploring the potential of combining IL-2-activated NK cells with an anti-PDL1 monoclonal antibody to target multiple myeloma-associated macrophages
title Exploring the potential of combining IL-2-activated NK cells with an anti-PDL1 monoclonal antibody to target multiple myeloma-associated macrophages
title_full Exploring the potential of combining IL-2-activated NK cells with an anti-PDL1 monoclonal antibody to target multiple myeloma-associated macrophages
title_fullStr Exploring the potential of combining IL-2-activated NK cells with an anti-PDL1 monoclonal antibody to target multiple myeloma-associated macrophages
title_full_unstemmed Exploring the potential of combining IL-2-activated NK cells with an anti-PDL1 monoclonal antibody to target multiple myeloma-associated macrophages
title_short Exploring the potential of combining IL-2-activated NK cells with an anti-PDL1 monoclonal antibody to target multiple myeloma-associated macrophages
title_sort exploring the potential of combining il-2-activated nk cells with an anti-pdl1 monoclonal antibody to target multiple myeloma-associated macrophages
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10198883/
https://www.ncbi.nlm.nih.gov/pubmed/36656341
http://dx.doi.org/10.1007/s00262-022-03365-4
work_keys_str_mv AT ehlersfemkeai exploringthepotentialofcombiningil2activatednkcellswithanantipdl1monoclonalantibodytotargetmultiplemyelomaassociatedmacrophages
AT mahaweninikenm exploringthepotentialofcombiningil2activatednkcellswithanantipdl1monoclonalantibodytotargetmultiplemyelomaassociatedmacrophages
AT vandewaterwegberendsannet exploringthepotentialofcombiningil2activatednkcellswithanantipdl1monoclonalantibodytotargetmultiplemyelomaassociatedmacrophages
AT sayathara exploringthepotentialofcombiningil2activatednkcellswithanantipdl1monoclonalantibodytotargetmultiplemyelomaassociatedmacrophages
AT bosgerardmj exploringthepotentialofcombiningil2activatednkcellswithanantipdl1monoclonalantibodytotargetmultiplemyelomaassociatedmacrophages
AT wietenlotte exploringthepotentialofcombiningil2activatednkcellswithanantipdl1monoclonalantibodytotargetmultiplemyelomaassociatedmacrophages